Evofem Biosciences (EVFM)
(Delayed Data from OTC)
$0.01 USD
0.00 (-16.67%)
Updated May 17, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Evofem Biosciences, Inc. [EVFM]
Reports for Purchase
Showing records 81 - 100 ( 118 total )
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AMPREVENCE Trial Completes Enrollment on Schedule; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Deal with PDL Paves the Way for Potential Launch in 2020
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Financing Transaction Marks New Strategic Investor Entry; Lowering Target to $10 Due to Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Our Expert Call on Amphora and the Contraception Market
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Part 3 - Which Niche Companies to See and Why at Our 31st ROTH Conference?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
FY2018 Financial Results Reported; Rising Expenses and Near-Term Capital Need; Moderating Target to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q18 - Closer - Closer to Potential Approval and Launch
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Join in Our Expert Call on Amphora and the Contraception Market on Mar. 7
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AMPOWER Phase 3 Trial Hits; Multiple Catalysts Approaching; Raising Target to $12.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Ph3 AMPOWER Results Demonstrate Amphora''s Contraception Power
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Amphora Pivotal Readout Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Yas'' Weekly Recap - What the Buy-side Reads
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y